ArticleTherapeutics and clinical risk management2018
The association between rs12901499 polymorphism in SMAD3 gene and risk of osteoarthritis: a meta-analysis.
Article in Therapeutics and clinical risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.
- Pooled it
- Association between the polymorphisms of CALM1 gene and osteoarthritis risk: a meta-analysis based on observational studies.Bioscience reports · 2018Pooled it
- SMAD3 Gene Polymorphisms and Protein Expression as Potential Biomarkers of Susceptibility to Knee Osteoarthritis.Cureus · 2026Article
- Joint Tissues: Convergence and Divergence of the Pathogenetic Mechanisms of Rheumatoid Arthritis and Osteoarthritis.International journal of molecular sciences · 2025Review
- Inhibition of SMAD3 effectively reduces ADAMTS-5 expression in the early stages of osteoarthritis.BMC musculoskeletal disorders · 2023Article
- The polymorphism of SMAD3 rs1065080 is associated with increased risk for knee osteoarthritis.Molecular biology reports · 2019Article
- Role ofJournal of orthopaedicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was conducted to assess and synthesize the current evidence on the association between rs12901499 polymorphism in SMAD3 gene and risk of osteoarthritis (OA). MATERIALS AND
methodsFour electronic databases, including PubMed, Embase, ISI Web of Science, and CENTRAL were systematically searched for potential studies. Summary odds ratio and corresponding 95% CI were calculated to evaluate the association. Risk of bias was assessed through the Newcastle-Ottawa Scale. Subgroups and sensitivity analyses were performed using the RevMan 5.3 software. Publication bias was evaluated by Egger's and Begg's tests. Power analysis was conducted using the Power and Sample Size Calculation program.
resultsEight case-control studies containing 5,625 patients with OA and 5,600 healthy controls were obtained for the meta-analysis. After excluding cohorts with inadequate power, the pooled data supported that G allele carriers of rs12901499 had a significantly increased risk of OA (odds ratio 1.31, 95% CI: 1.21 to 1.43,
conclusionThe combined results evidently supported that rs12901499 polymorphism in SMAD3 gene is significantly associated with OA vulnerability across both Caucasian and Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.